BioSpace News Archive

Emmaus Life Sciences, Inc. today announced real-world data on Endari®, the company’s prescription-grade L-glutamine oral powder, in preventing acute complications from sickle cell disease (SCD) and hemolysis in pediatric and adult patients in French Guiana and Qatar.

Synthekine Inc today announced five poster presentations based on research spanning each of its three distinct cytokine engineering platforms at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, LA from April 8-13, 2022.

Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 1:30 p.m.

BriaCell Therapeutics Corp. announces that its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.

Claritas Pharmaceuticals, Inc. is pleased to announce that it has obtained approval from the OTC Markets Group for listing of its Common Shares on the OTCQB.

RedCloud Bio announced the upcoming presentation of preclinical data of H002, a next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in non-small lung cancer (NSCLC).

Lexicon Pharmaceuticals, Inc. announced that Jeffrey L. Wade, Lexicon’s president and chief financial officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 8:45 a.m. ET.

Propella Therapeutics, Inc. (“Propella”), and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm), today announced that the companies have entered into an exclusive licensing agreement for CGS-200-5, a clinical-stage topical treatment that is being developed for the treatment of pain in patients with moderate to severe osteoarthritis (OA) of the knee.

CorMedix Inc. today announced the formation of a new Scientific Advisory Board (SAB) comprised of esteemed experts in nephrology, infectious disease, medical nutrition, and pediatric oncology.

BioSig Technologies, Inc. today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, will be presenting at NobleCon18 - Noble Capital Markets’ Eighteenth Annual Investor Conference.